Symphar S.a.

Hoffmann-la Roche Inc.

Ilex Products, Inc.

Other

Smithkline Beecham Corporation

Ilex Oncology Research S.a.

Eric Joseph Niesor

Craig Leigh Bentzen

Hieu Trung Phan

Lan Mong Nguyen

Raymond Azoulay

Vinh Van Diep

Robert John Ife

Yves Guyon-Gellin

Jean-Claude Tardif

Marie-Pierre Dube

Ruchi Upmanyu

Simon Floret

Lan Nguyen Mong

Pierre Maechler

Lan N Mong

Alexandre Bulla

Bernd Kuhn

Uwe Grether

Hans G Richter

Rainer Eugen Martin

Philippe Pflieger

Henrietta Dehmlow

Konrad H Bleicher

Torsten Hoffmann

Holger Kuehne

Minmin Yang

Matthew Wright

Narendra Panday

Alexander Chucholowski

Gregory Martin Benson

Franz Schuler

Jean-Luc Thuillard

Xavier Marie Warot

Jean Flach

Kyriacos Kalathakis

Lân Mong Nguyen

Jean-Robert Rossier

Yves Gyon Gellin

Anne Perez

Jean-Luc Thulliard

Harald Eschenhof

The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

CETP inhibitors for therapeutic use

Dalcetrapib for therapeutic use

The invention is concerned with compounds of formula I: wherein R, R, and Q are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are useful as inhibitors of cholesteryl ester transfer protein (CETP).

Compounds

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.

Benzimidazole derivatives

The present invention relates to methods of use of aminodiphosphonate to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states.

Aminodiphosphonate apolipoprotein E modulators

The present invention relates to novel &#x3b2;-substituted-&#x3b2;-aminoethylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering plasma levels of total cholesterol.

&#x3b2;-substituted &#x3b2;-aminoethyl phosphonate derivatives

The present invention relates to novel &agr;-substituted-&bgr;-aminoethylphosphonate and &agr;-substituted-&bgr;-aminovinylphosphonate derivatives and their uses for lowering plasma levels of apo (a), Lp(a), apo B, apo B associated lipoproteins (low density lipoproteins and very low density lipoproteins) and for lowering plasma levels of total cholesterol.

&agr;-Substituted &bgr;-aminoethyl phosphonate derivatives

Aminophosphonates alpha substituted by phenol groups of formula (I) have lipoprotein(a) lowering activity.

Compounds and pharmaceutical compositions containing them

Aminophosphonates alpha substituted by phenol groups, of formula (I) have lipoprotein(a) lowering activity.

Pharmaceutical aminophosphonic acid derivatives

Use of phenol substituted diphosphonates as antineoplastic agents

The present invention relates to novel aminophosphonate derivatives substituted in .alpha. position by phenol groups, of formula (I): ##STR1## in which: X.sup.1, X.sup.2, X.sup.3, R.sup.1, R.sup.2, A, B, Z and n are defined in claim 1, as well as their preparations and the pharmaceutical compositions comprising them.

Substituted aminophosphonate derivatives, process for their preparation

The invention relates to new gem-diphosphonates derivatives substituted by phenol groups of formula (I): ##STR1## as well as the process for their preparation and the pharmaceutical compositions containing them.

Method for lowering plasma lipid levels or blood pressure

Phenol substituted gem-diphosphonate derivatives, process for their

Growing community of inventors

Nyon, Switzerland

Eric Joseph Niesor